IQ-AI Regulatory News (IQAI)

IQ-AI Ltd

("IQ-AI" or the "Company")

Board Changes

IQ-AI Appoints Renowned Brain Tumor Champion to Board of Directors

IQ-AI Ltd (LSE: IQAI) is pleased to announce the appointment of Dr. Al Musella, MD, as a Non-Execuitve Director. Dr. Musella brings almost three decades of experience as founder and president of the Musella Foundation for Brain Tumor Research and Information, Inc.

Dr. Musella formed the first online support group for brain tumor patients in 1993, which has since evolved into the compreshensive resource website, virtualtrials.org. Under his leadership, the Musella Foundation has made many significant contributions to the brain tumor community including funding novel research, advocating for the approval of new treatments, and helping patients access needed treatments with financial support.

Dr Musella has issued more than $19.3 million in brain tumor research grants and co-payment assistance grants to help patients access needed treatments. He also advocated for FDA and Medicare approval for Optune, Temodar, Gliadel, Gleolan, Avastin and many other treatments. His current efforts include lobbying for the "Promising Pathway Act," legislation that accelerates the clinical trial approval process in order to move new drugs to market more efficiently.

"We are pleased to welcome Dr. Musella to our Board of Directors," said Trevor Brown, CEO of IQ-AI. "His extensive network and experience will be invaluable as we forge ahead in the development of oral gallium maltolate and build upon our core imaging business".

Dr. Musella commented, "I am honored to join IQ-AI and the Imaging Biometrics team, and I look forward to contributing to their efforts of helping brain tumor patients and the clinicians who support them".

No information is required to be disclosed pursuant to paragraph 9.6.13R of the Listing Rules.

 As part of these Board Changes, Vinod Kaushal will step down as non-executive director with immediate effect.

--ENDS-

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

About Imaging Biometrics® LLC:  IB is a wholly owned subsidiary of IQ-AI Limited, (LON: IQAI), and focuses on delivering quantitative imaging platforms and therapeutics that transform how clinicians diagnose and treat patients more efficiently and effectively. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com. Follow IB on Twitter, @IQAI_IB.